Halozyme Announces FDA Approval of Bristol Myers Squibb's …
Dec 30, 2024 · Halozyme Therapeutics, Inc. (NASDAQ: HALO) (Halozyme) today announced that Bristol Myers Squibb received U.S. Food and Drug Administration (FDA) approval for Opdivo Qvantig™ (nivolumab and ...
Halozyme to Host Investor Conference Call to Provide Updated …
1 day ago · Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced it will host an Investor Conference Call on Wednesday, January 8, 2025, at 5:30 a.m. PT / 8:30 a.m. ET. News Today's news
Halozyme Announces argenx's VYDURA with ENHANZE® was …
Dec 30, 2024 · News provided by Halozyme Therapeutics, Inc. Dec 30, 2024, 06:45 ET. Share this article. Share to X. Share this article. Share to X. SAN DIEGO, Dec ...
News | Halozyme
2 days ago · Halozyme provides disruptive drug delivery solutions with the goal of improving patient experiences and outcomes that can enhance the competitiveness of emerging and established therapies. To catch up on our latest news, updates and Industry Insights, please review the links below:
Halozyme drops Evotec buyout bid; Patient dies in Neurogene trial
Nov 22, 2024 · Halozyme Therapeutics on Friday said it withdrew an offer to buy Evotec after the German drug discovery and contracting company refused to engage in acquisition talks.
Halozyme Provides Update on Non-Binding Proposal to Combine …
SAN DIEGO, Nov. 18, 2024 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme" or the "Company") today provided an update on its non-binding proposal to acquire Evotec SE...
Halozyme Announces Expansion of Global Collaboration and …
Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that argenx has nominated four new targets under its global collaboration and license agreement that provides argenx exclusive access to...
Halozyme makes 2 billion euro buyout offer for drug developer …
Nov 14, 2024 · Halozyme Therapeutics said on Thursday it has proposed to buy German drug developer Evotec for about 2 billion euros ($2.10 billion), to bulk up its drug discovery and development portfolio.
Halozyme Announces Positive Clinical Data of its High-Volume …
Oct 16, 2023 · Study met primary end point and demonstrated successful subcutaneous administration of a 10 mL biologic co-formulated with ENHANZE® in 30 seconds using Halozyme's proprietary high-volume...
Halozyme ends $2B bid for Evotec, biotech “unwilling to engage”
Nov 22, 2024 · Halozyme Therapeutics has withdrawn its $2.1 billion offer to buy Evotec after the German company “has been unwilling to engage with us to explore a potential combination,” Halozyme president and...